# OnCo record nct03175224 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03175224/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03175224", "NCT03175224" ;
  schema:name "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors"@en ;
  schema:alternateName "SPARTA"@en ;
  schema:description "A phase 2 trial of Vebreltinib in metastatic cancer and thyroid cancer, run by Apollomics Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03175224/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03175224> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2017-09-27" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/thyroid/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/vebreltinib/> ;
  onco:companies <https://onco.cc/companies/apollomics/> .